Wassim Mourtada - Chief Executive Officer

Mr. Mourtada was formerly Associate Director of the University of Michigan's Center for Venture Capital and Private Equity Finance, a not-for-profit research group serving venture capital & private equity firms, institutional investors, corporations, governments, managers and entrepreneurs.

Mr. Mourtada's primary research focus at the Center was studying issues faced in the commercialization of research-institution originated intellectual property as well as the evolving structure of the private equity industry. Some of his research has been published by the Federal Reserve Bank, the Government of France's Conseil du Credit et du Titre and the Financial Management Association.

His focus on research commercialization and technology transfer is nationally noted and he was the Chairman of the Advisory Board of the Inaugural Research Commercialization Conference, held in Boston in November 2003. This conference brought together, national level constituents from industry and academia around the subject of building and financing spinouts and included organizations such as Harvard, Yale, MIT, Columbia, Caltech, Stanford, Lawrence Berkeley National Labs, Los Alamos National Lab, Boeing, DuPont, P&G, Intel, Microsoft, Lucent, Eastman, MPM Capital, ARCH Ventures, Sprout Group and Draper, Fisher & Jurvetson.

He is a major contributor to one of the more notable publications in the field: "Taking Research to Market: How to Build and Invest in Successful University Spinouts", published in 2004 by Euromoney.

Mr. Mourtada was instrumental in the startup and financing of Genetics Squared, a leader in the personalized medicine space. Today Genetics Squared is engaged with major universities and pharmaceutical companies and will be releasing its first product onto the market in 2009: a unique diagnostic in oncology.

Mr. Mourtada was born in 1974 and has earned two degrees from the University of Michigan in Economics and in Engineering.

Envision's Leadership

Industry-leading professionals with unique expertise, insight, visibility, market presence and credibility:

• Commercialised technologies from lab to commercial sale that have resulted in over US$ 1bn in aggregate revenues, including several industry "firsts"
• Managed venture capital funds that have been in the top 5% of their vintage class
• Founded and operated successful and mature start-up companies in biotechnology, nanotechnology and financial services
• Participated in over $5bn in equity raising, debt raising and M&A
• Formally advised governments on their venture capital and technology initiatives, including Austria, Abu Dhabi, Spain, State of California, State of Michigan, Kingdom of Saudi Arabia, Singapore and South Africa